ERBB2 and gastric cancer: Immune checkpoint inhibitors, in combination with standard therapy, improve OS in both HER2-negative and HER2-positive GC according to the KEYNOTE-811, CheckMate-649, and KEYNOTE-859 trials [58,59,60].